Navigation Links
Micell Technologies' Rapid Absorption Polymer DES System to be Presented at CRT 2009
Date:3/4/2009

RALEIGH, N.C., March 4 /PRNewswire/ -- Micell Technologies announced today that David E. Kandzari, MD, will present "The Micell Rapid Absorption Polymer DES System" during the Cardiovascular Research Technologies (CRT) meeting in Washington, DC, on March 5, 2009. MiStent(TM), a Drug-Eluting Stent (DES) in pre-clinical studies, utilizes a bioasorbable polymer coating that delivers the potential benefits of the drug during the healing process. The proprietary formulation allows the polymer to be absorbed concurrent with the drug delivery rather than sequentially like other absorbable DES coatings. This allows both the polymer and drug to be eliminated within 90 days and provides the potential for improved patient benefits.

"The Micell DES technology is exciting because it is the first of a new generation of stents being developed to precisely deliver a drug while safely eliminating the polymer faster than any other bioabsorbable coating that is commercially available," said Kandzari. "The unique formulation that allows the polymer to be absorbed at the same time that the drug is being delivered offers the therapeutic benefits of a drug-eluting stent, while quickly transforming itself to the safety profile of a bare metal stent."

Earlier this year, Micell obtained the rights to a CE marked cobalt chromium stent to use as its platform for its proprietary coating. Arthur J. Benvenuto, Chairman and Chief Executive Officer of Micell, said, "The pieces are quickly coming together as we demonstrate the advantages of our proprietary formulation and deliver it on a state-of-the-art stent with the lowest strut thickness commercially available. Our scalable drug and polymer coating process serves as a platform for the development of innovative interventional cardiology systems."

Dr. Kandzari is the Director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, CA.

About Micell Technologies Inc.

Micell Technologies is a privately-held, development-stage biomedical device company dedicated to developing innovative interventional cardiology systems. By applying its unique surface and polymer modification technologies, Micell can precisely and consistently control drug elution and the duration of polymer exposure creating the potential for a therapeutic solution for coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Its first product in development, MiStent(TM), is a rapid absorbing coated drug-eluting stent with precise control of drug release and pharmacokinetics. Visit us at www.micell.com.

    Contact: Micell Technologies

    Arthur J. Benvenuto, Chairman & CEO
    (919) 313-2104


'/>"/>
SOURCE Micell Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Micell Rapid Absorption Polymer DES System to be Presented at TCT 2008
2. Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
7. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
8. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
9. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
10. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of Investment’s ... in San Francisco. Located at booth number 7301, representatives from the Thai Government, ... discuss the Thai biotechnology and life sciences sector. , Deputy Secretary General ...
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the variety ... that could lead to one good one. Surviving Mesothelioma has just posted an article ... team evaluated 98 mesothelioma patients who got a second kind of drug ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... diabetes, and traumatic injuries, will be accelerated by research at Worcester Polytechnic Institute ... engines of wound healing and tissue regeneration. , The novel method, developed by ...
(Date:5/23/2016)... ... ... The need for blood donations in South Texas and across the nation is growing. , ... Center, blood donations are on the decline. In fact, donations across the country are at ... South Texas in the last four years alone. , There is no substitute for blood. ...
Breaking Biology Technology:
(Date:3/9/2016)... , March 9, 2016 This BCC Research ... states of the RNA Sequencing (RNA Seq) market for ... as instruments, tools and reagents, data analysis, and services. ... segments of the RNA-Sequencing market such as RNA-Sequencing tools ... the main factors affecting each segment and forecast their ...
(Date:3/9/2016)... GARDENS, Fla. , March 9, 2016 /PRNewswire/ ... management authentication and enrollment solutions, today announced the ... DigitalPersona ® Altus multi-factor authentication platform. ... and InfoSec managers to step-up security where it,s ... Washington, DC . ...
(Date:3/3/2016)...  FlexTech, a SEMI Strategic Association Partner, awarded five ... Development, Leadership in Education, and, in a category new ... year of the FLEXI Awards and the winners ... past years . Judging was done on a ... criteria, by a panel of non-affiliated, independent, industry experts. ...
Breaking Biology News(10 mins):